Congratulations to IMB’s Dr Markus Muttenthaler who received the Miklós Bodanszky Award for his outstanding contributions to peptide science. 

Thanks to a $1.3 million state government research grant, IMB’s Dr Nathan Palpant has partnered with Professor John Fraser at The Prince Charles Hospital to develop next generation medical treatments to tackle heart disease, which claims the life of one Australian every 12 minutes.

Paralympian Chris Bond was 19 when a severe bacterial infection in his bowel spread through his body and sent him into septic shock. Today, on World Sepsis Day (13 September), Chris is working with IMB's Community for Open Antimicrobial Drug Discovery (CO-ADD) to bring attention to the multidrug-resistant bacteria that nearly took his life.

Inflazome Ltd, a company founded on research from The University of Queensland (UQ) and Trinity College Dublin, has closed a Series A financing round of up to €15 million (A$22 million).

IMB’s Mathilde Desselle has won the Queensland Women in Technology (WiT) InfoTech Professional Award for her leadership of biomedical research programs and facilities in the fields of genomics, bioinformatics and drug discovery.

IMB research could lead to a new treatment for Parkinson’s disease, with future potential applications to nearly 50 other disorders.

Researchers from IMB and Imperial College London have developed a method to distinguish viral and bacterial infections in children, which will save lives and reduce antibiotic use.

IMB researcher Professor Kirill Alexandrov has received funding from the Bill & Melinda Gates Foundation to develop a cheap, portable biosensor to detect a range of infectious diseases, including Dengue fever and Zika virus.

IMB spin-out biotech company Protagonist Therapeutics Inc is a step closer to developing a new drug that would benefit millions of people worldwide.